

REFERENCE

1. M. D. A. Ribeiro et al. 2018. “Guidelines for the diagnosis, treatment and prevention of leprosy,” World Heal. Organ. Vol. Jan, no. 2, pp. 1–7, 2020.
2. Zodpey SP, Tiwari RR, Salodkar AD. Gender differentials in the social and family life of leprosy patients. *Lepr Rev.* 2000; 71:505–510. [[PubMed](#)] [[Google Scholar](#)]
3. Effectiveness Analysis of Single Dose Rifampicin for Preventing Leprosy transmission. *JPHTCR.* Vol. 4. No. 2 (2021). <http://ejournal2.undip.ac.id/index.php/jphtr/index>.
4. Moet FJ et al: Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. *BMJ.* 2008, 336 (7647): 761-764. 10.1136/bmj.39500.885752.BE.
[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
5. WHO towards zero leprosy NTD road map 2030 in April 2021. Available on; '[Towards Zero Leprosy -- Global Leprosy \(Hansen's disease\) Strategy 2021--2030](#)'
6. Towards zero leprosy, global leprosy strategy 2021–2030. Geneva: World Health Organization; 2021 (<https://www.who.int/publications/i/item/9789290228509>).
7. Leprosy annual report at SEAR 2020. Available on;
<https://apps.who.int/gho/data/node.main-searo.A1639?lang=en>
8. The National health sector strategic plan (2011-2030), towards a “Health East Timorese people in a Healthy Timor-Leste” (page 55). Available on;
<https://cdn.who.int/media/docs/default-source/searo/timor-leste/national-health-sector-plan.pdf>
9. UNMIT, “Leprosy no longer public health threat in Timor-Leste,” Press Release.
<https://reliefweb.int/report/timor-leste/leprosy-no-longer-public-health-threat-timor-leste>
(accessed Dec. 11, 2021).
10. WHO. Elimination of leprosy: resolution of the 44th World Health Assembly (Resolution No. WHA 44.9). Geneva: WHO; 199. [Google Scholar](#)
11. MOH, “Final of National Leprosy Strategic plan 2021-2025-Tetum&English.” 2021.
12. Leprosy Today [webpage on the Internet] Geneva: World Health Organization; c2011. [Accessed February 22, 2012]. [cited 2012 May 28]. Available on;
<http://www.who.int/lep/en/> [[Google Scholar](#)]

13. United Nation Development Programme (UNDP), 2011. *National Health Sector Strategic Plan* (NHSSP) 2011-2030. Ministry of Health, Dili, Timor-Leste. Taliti.
14. Leprosy/Hansen disease: Contact tracing and post-exposure prophylaxis. Technical guidance WHO 2020. Available on; <https://apps.who.int/iris/handle/10665/336679>
[Google Scholar](#)
15. Jan Hendrik Richardus , J Dik F Habbema. The impact of leprosy control on the transmission of *M. leprae*: is elimination being attained. *Lepr Rev.* 2007 Dec; 78 (4):330-7. [[PubMed](#)] [[Google Scholar](#)]
16. Rees RJW, Young DB. The microbiology of leprosy. In: Hastings RC, editor. *Leprosy*. 2nd ed. New York: Churchill Livingstone; 1994. p.49-83.
17. Global Leprosy Strategy 2016–2020. Accelerating towards a leprosy-free world. Monitoring and Evaluation Guide. Available on;
https://apps.who.int/iris/bitstream/handle/10665/208824/9789290225096_en.pdf
18. Shepard CC. The nasal excretion of *Mycobacterium leprae* in leprosy. *Int J Lepr.* 1962;30:10–18. [[PubMed](#)] [[Google Scholar](#)]
19. Job CK. Nasal mucosa and abraded skin are the two routes of entry of *Mycobacterium leprae*. *Star.* 1990;49:1. [[Google Scholar](#)]
20. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser. 1982;675:1–33. [[PubMed](#)] [[Google Scholar](#)]
21. WHO Expert Committee on Leprosy World Health Organ Tech Rep. Ser. 1988;768:1–51. [[PubMed](#)] [[Google Scholar](#)] (classification)
22. Ridley DS, Jopling WH. A classification of leprosy for research purposes. *Lepr Rev.* 1962;33:119–128. [[PubMed](#)] [[Google Scholar](#)]
23. Acceptability of chemoprophylaxis in an endemic area for leprosy: the PEP-Hans Brazil Project. Available on; <https://doi.org/10.1590/0102-311X00068719>
24. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. [Mandeep Sekhon](#), [Martin Cartwright](#) & [Jill J. Francis](#). [[BMC Health Services Research](#) **17**], Article number: 88 (2017)
25. Sidani S, Epstein DR, Bootzin RR, Moritz P, Miranda J. Assessment of preferences for treatment: validation of a measure. *Res Nurs Health.* 2009;32(4):419.
[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
26. Patient-related factors predicting the effectiveness of rifampicin chemoprophylaxis in contacts: 6 year follow up of the COLEP cohort in Bangladesh. Randomized Controlled Trial. *Lepr Rev.* 2012 Sep;83(3):292-304. Sabiena G Feenstra . . [[PubMed](#)]

27. Chemoprophylaxis in the prevention of leprosy. [W Cairns S Smith](#), *BMJ*. 2008.
28. Role of contact tracing and prevention strategies in the interruption of leprosy transmission. W Cairns S Smith, Ann Aerts. PMID: 24974438 . [[PubMed](#)]
29. WHO. Elimination of leprosy as a public health problem. *Wkly Epidemiol Rec* 1998;73:308-12. [[PubMed](#)] [[Google Scholar](#)]
30. Smith CM, Smith WCS. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. *J Infect* 2000; 41:137-42. [[PubMed](#)] [[Google Scholar](#)]
31. MI Bakker, M Hatta, A Kwenang, *et al*. Prevention of leprosy using rifampicin as chemoprophylaxis *Am J Trop Med Hyg*, 72 (2005), pp. 443-448
[View PDF CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)
32. RV Wardekar DDS prophylaxis against leprosy. *Lepr India*, 39 (1967), pp. 155-159.
[View Record in Scopus](#) [Google Scholar](#)
33. Global Leprosy, “Towards zero leprosy Towards zero leprosy,” pp. 1–30, 2021
34. Daumerie D. Implementation of MDT-Successive steps. In: Sansarricq H, editor. *Multidrug therapy against leprosy: Development and implementation over the past 25 years*. Geneva: WHO Library Cataloguing-in-Publication Data; 2004. pp. 45–57. [[Google Scholar](#)]
35. WHO Study Group. WHO Technical Report Series no. 847. Geneva: World Health Organization; 1994. *Chemotherapy of leprosy*. [[Google Scholar](#)]
36. H. Apte et al 2019. Acceptability of contact screening and single dose rifampicin as chemoprophylaxis for leprosy in Dadra and Nagar Haveli, India [Google Scholar](#)
37. Sabina.G.F et al 2011. Acceptability of chemoprophylaxis for household contacts of leprosy patients in Bangladesh: a qualitative study. [[PubMed](#)] [[Google Scholar](#)]
38. R. Peters et al, 2018. A single dose of rifampicin to prevent leprosy: qualitative analysis of perceptions of persons affected, contacts, community members and healthb professionals towards chemoprophylaxis and the Impact on their attitudes in India, Nepal and Indonesia. [[Google Scholar](#)]
39. Da Cortela DCB, Ferreira SMB, Virmond MCL *et al*. Acceptability of chemoprophylaxis in an endemic area for leprosy: The PEP-HANS Brazil Project. *Cadernos de Saude Publica*. Available on; <https://doi.org/10.1590/0102-311x00068719>